Skip to main content
Signal8

NorthStrive Biosciences to Advance EL-22 Manufacturing Characterization with Quantitative FACS Analysis of Latent Myostatin Antigen Expression

$ELABPress releaseJul 10, 2026, 7:30 AM ET

NorthStrive Biosciences, a subsidiary of PMGC Holdings, announced plans to initiate an independent flow cytometry program to characterize its EL-22 therapeutic candidate. The study aims to quantify latent myostatin antigen expression on NorthStrive-manufactured Lactobacillus casei and establish comparability with material previously produced by MOA Life Plus.

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    ELAB: NorthStrive Biosciences to Advance EL-22 Manufacturing Characterization with Quantitative FACS Analysis of Latent Myostatin Antigen Expression — AI Analysis | Signal8